Acute Ischemic Stroke Interventional Study

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT03803007

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Acticor Biotech (from the registry)
Registry
  • NCT NCT03803007
  • EudraCT 2018-002855-13
Other papers using this trial's data
  • Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial The Lancet. Neurology, 2024-02 DOI, PubMed 38267188

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03803007. Randomized; triple masking; primary purpose treatment. Start 2019-03-06 (actual); primary completion 2021-09-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Acute Ischemic Stroke Interventional Study
Acronym
ACTIMIS
Condition
Acute Ischemic Stroke
Intervention (Drug)
Intravenous ACT017 1000 mg
Intervention (Other)
Intravenous Placebo
Lead sponsor
Acticor Biotech (class: industry)

Record details

Record id
cardio:ct-nct03803007
Content hash
8dfc191b7998dc6b86c1da1475294cd371d60eea9bcd6f9bc913b052c0492859